Methods for diagnosing and treating oncogenic kras-associated cancer
Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
1. A method for treating a subject having a cancer comprising an oncogenic Kras mutation, the method comprising
detecting that a sample obtained from the subject comprises an elevated level of expression of ribulose-5-phosphate-3-epimerase (RPE) compared to a control sample lacking an oncogenic Kras mutation, and
inhibiting RPE or ribose 5-phosphate isomerase A (RPIA) in the subject, thereby treating the subject.
2. The method of claim 1 , wherein said subject has been previously determined or is simultaneously determined to have a cancer comprising the oncogenic Kras mutation.
3. The method of claim 2 , wherein said Kras mutation is selected from the group consisting of Kras G12D , Kras G12V , Kras G13D , Kras G12C , Kras Q61R Kras Q61L , Kras Q61K , Kras G12R , and Kras G12C .
4. The method of claim 1 , wherein said cancer is selected from the group consisting of pancreatic cancer, non-small cell lung cancer, colorectal cancer, and biliary cancer.
5. A method comprising:
(1) providing a sample from a subject, wherein the sample comprises an oncogenic Kras mutation;
(2) detecting that said sample comprises an elevated level of expression of ribulose-5-phosphate-3-epimerase (RPE) compared to a control sample lacking the oncogenic Kras mutation, and
(3) inhibiting RPE or ribose 5-phosphate isomerase A (RPIA) in the subject.
6. The method of claim 5 , wherein said subject has been previously determined or is simultaneously determined to comprise an oncogenic Kras mutation.
7. The method of claim 6 , wherein said Kras mutation is selected from the group consisting of Kras G12D , Kras G12V , Kras G13D , Kras G12C , Kras Q61R , Kras Q61L , Kras Q61K , Kras G12R , and Kras G12C .
8. The method of claim 5 , wherein the subject has pancreatic cancer, non-small cell lung cancer, colorectal cancer, or biliary cancer.
9. The method of claim 1 , wherein RPE is inhibited by administering to the subject an antisense oligonucleotide that targets RPE or a small interfering RNA that targets RPE.
10. The method of claim 1 , wherein RPIA is inhibited by administering to the subject an antisense oligonucleotide that targets RPIA or a small interfering RNA that targets RPIA.
11. The method of claim 5 , wherein RPE is inhibited by administering to the subject an antisense oligonucleotide that targets RPE or a small interfering RNA that targets RPE.
12. The method of claim 5 , wherein RPIA is inhibited by administering to the subject an antisense oligonucleotide that targets RPIA or a small interfering RNA that targets RPIA.